Little is known about the genetic impact on loop diuretic effects. We newly investigated five genetic polymorphisms in 95 healthy volunteers, who had ingested bumetanide, frusemide and torsemide. The subjects excreted means of 20.2 g sodium chloride, 2.87 g potassium and 261 mg calcium over 24 h. Concerning sodium chloride, the subjects excreted 2.2 g less per two T-alleles of C825T in the G nucleotide b-subunit 3 (GNB3), 3.2 g less per two Met32-alleles of Val32Met in the atrial natriuretic peptide precursor (ANP) and 2.8 g more per two Arg152-alleles of Ter152Arg in ANP (P ¼ 0.007, 0.05 and 0.007). Concerning potassium, the subjects excreted 0.42 g more per two ANP Arg152-alleles (P ¼ 0.023). Concerning calcium, the subjects excreted 32 mg more per two deletion-alleles of the insertion/ deletion polymorphism in the angiotensin-converting enzyme, 44 mg more per two Trp460-alleles of Gly460Trp in a-adducin (ADD1) and 42 mg less per two GNB3 T-alleles (P ¼ 0.006, 0.023 and 0.008). The common genetic impact together with three polymorphisms in the sodium chloride cotransporter and the epithelial sodium channel was 20, 15, 10 and 23% of the variation in the urinary excretion of sodium chloride, volume, potassium and calcium. This exceeded the fraction of variation explained by differences in the pharmacokinetics: 13, 10, 11 and 6%. Thus, genetic variation seems to be a stronger predictor of the loop diuretic drug response than pharmacokinetic variation.
Introduction
Loop diuretics are widely used, especially in patients with hypertension or heart failure plus renal dysfunction. Such patients are particularly susceptible to untoward drug effects. It is, therefore, appreciable, to predict patients' individual responses to loop diuretics. Genetic polymorphisms are potential biomarkers to predict individual responses but little is known about the genetic impact on loop diuretic effects.
Three polymorphisms are known to affect the loop diuretic response. 1 One is Gly264Ala in the sodium chloride cotransporter (NCC). Another one is the most frequent haplotype (H2_1) in the 3 0 -linkage block of the gene encoding the b-subunit of the epithelial sodium channel ENaC. The third is the Leu649Leu polymorphism in ENaC's g-subunit. No polymorphism in the loop diuretic target, the sodium-potassium-di-chloride-cotransporter 2 was found to affect the loop diuretic response.
Five other genetic polymorphisms are known to affect the thiazide diuretic response. One is the C825T polymorphism in the G nucleotide b-subunit 3 (GNB3, rs5443). [2] [3] [4] Two others are Val32Met and Ter152Arg in the atrial natriuretic peptide precursor (ANP, rs5063 and rs5065). 5, 6 A further one is an insertion/deletion polymorphism in the angiotensin-I-converting enzyme (ACE I/D, rs1799752. 4, 7, 8 The fifth is Gly460Trp in a-adducin (ADD1, rs4961). 4, [8] [9] [10] We investigated how the latter five polymorphisms affected loop diuretic drug effects after single oral doses in healthy volunteers. We then evaluated how much interindividual variation in loop diuretic drug effects is explained by the altogether eight genetic polymorphisms in relation to how much is explained by pharmacokinetic variation.
Materials and methods
A total of 95 healthy, male Caucasian volunteers had participated in a clinical study on the diuretic effects of loop diuretic drugs. 1 The study has been approved by the ethics committee of Göttingen University (No. 24/7/02) and was performed adhering to the Declaration of Helsinki. All participants provided written informed consent before their inclusion into the study. Most participants were students at Göttingen University. Their mean age was 28 years, mean body weight was 78 kg and mean height was 182 cm with body mass indices between 18 and 25 kg m -2 . 1 The study was a randomized, single-blind, three-arm, triple-crossover cohort study. The subjects ingested each a single oral dose of 2 mg bumetanide (Burinex, EMRA-MED, Trittau, Germany), 80 mg frusemide (Lasix, Aventis, Frankfurt, Germany) and 10 mg torsemide (Unat, Roche, Grenzach-Wyhlen, Germany) at 2 weeks intervals. The subjects were asked to keep a salt-restricted diet from 48 h before 24 h after drug administration. Blood and urine were collected interval-wise for 24 h after drug intake.
To calculate the urinary electrolyte excretion, the individual clearances of volume, electrolytes and creatinine were calculated interval-wise. We divided the individual electrolyte clearance in the respective intervals by the corresponding individual creatinine clearance. The resulting 'fraction excreted' is a standard measure of renal functions. The Fe has been proposed to best describe the pharmacodynamic effects of loop diuretics. 11, 12 The Fe represents the fraction, for example of an electrolyte, which has been excreted in the urine in relation to the amount, which was glomerularly filtered.
The Fe was transformed to gram amounts for comparability and comprehensibility. Multiplying the Fe values with 7.2 l h -1 as standard glomerular filtration rate resulted in the normalized electrolyte clearance. All numbers in this report refer to subjects with 7.2 l h -1 creatinine clearance. Multiplying these normalized electrolyte clearances with mean serum electrolyte concentrations and the interval duration resulted in the molar amount excreted during the respective interval. The molar amounts were multiplied with the molar weights to result in gram amounts.
All polymorphisms were genotyped using standard molecular biology techniques as described previously. 4, 6 A total of 20% of the samples were genotyped in duplicates and showed 100% concordance between the genotype calls. All polymorphisms were in Hardy-Weinberg equilibrium. The genotype frequencies given in Table 1 were in accordance with reported frequencies. When given numbers differ from the total number of subjects in the cohort, subjects were not included for technical reasons with the individual genotyping.
Statistics
The associations of the pharmacodynamic parameters with the polymorphisms were analyzed by covariance analysis (ANCOVA) using the software package SPSS, version 12.0 for Windows. Terms included for control reasons were: the different study days and the interaction of the study days with the amount of study drug, individually excreted during the respective period; the latter was normalized to a glomerular filtration rate of 7.2 l h -1 alike the electrolytes. We also controlled for the impact of the three polymorphisms formerly reported to influence loop diuretic effects. To calculate the association strength of the pharmacodynamics with the polymorphisms, the polymorphisms were included as main effect terms in the covariance model. P-values are given without adjustment for the number of tests. We acknowledge the problem of multiple testing. Rigid a-adjustment is, however, not appropriate in exploratory studies such as this. The results must be interpreted with the appropriate caution. The minor alleles are those with the commonly minor frequency. Concerning the five polymorphisms, these are the second-named alleles: the D-allele, the Trp-allele, the T-allele, the Met-allele and the Arg-allele. The numbers denote the numbers of subjects with the respective genotype in this study cohort. The numbers do not sum up to the total number of subjects in the cohort as the genotypes were not available in each subject for technical reasons. To estimate effect sizes on the respective days, the polymorphisms were included as interaction terms with the study days. The classification of the effect sizes relied on 'Cohen's d': The respective absolute effect size of a polymorphism was divided by the respective standard deviation in the total study cohort. Values below 0.3 denote small effects, values between 0.3 and 0.8 denote medium effects and values above 0.8 denote large effects. Also the estimates of the common genetic impact relied on these covariance analyses. The attributed fractions of variation are the 'partial eta-square' values attributed to the amount of drug excreted with the urine over 24 h, or attributed to the polymorphisms, respectively.
Results
In a three-arm triple-crossover human pharmacological study in 95 young, healthy volunteers, 2 mg bumetanide and 80 mg frusemide had nearly identical diuretic effects and torsemide at 10 mg, as expected, was somewhat weaker effective ( Table 2 ). The urinary excretion of sodium, chloride and volume peaked during the first hours after drug intake ( Figure 1 ). With potassium and calcium, the early peak was less pronounced. Within the first 6 h, 81, 86 and 73% of sodium, chloride and volume were excreted, but only 52 and 59% of potassium and calcium.
Sodium chloride and volume
The polymorphism in GNB3, the two ANP polymorphisms and two formerly reported polymorphisms, each affected the urinary sodium chloride excretion statistically significantly (grey shaded bars in Figure 2 , given effect sizes are from common ANCOVA, original data in Table 3 ). The impact of the polymorphisms on the excretion of sodium paralleled their impact on the chloride excretion (Figure 2 ). Among the three loop diuretics, most effects were consistently observed (Figure 3) .
Carriers of two GNB3 T-alleles excreted 2.2 g d -1 less sodium chloride compared to carriers of two C-alleles (P ¼ 0.007, Figure 2 ). To calculate the relative effect size, this was divided by the mean standard deviation of the sodium chloride excretion: 4.2 g d -1 . With 52% the effect of the GNB3 polymorphism was medium in size by the definition of Cohen. Compared with the total urinary sodium chloride excretion, the effect size of the polymorphism was 11% of 20.2 g d -1 . During the 24 h study period, the direction of the association between sodium chloride excretion and GNB3 polymorphism turned ( Figure 4 ). This turn was independently observed with all three-loop diuretics. During the first hours, carriers of the GNB3 T-allele excreted less sodium chloride. However, with time, the impact of the GNB3 polymorphism faded until it was absent in the 8-10 h period. Thereafter, and opposite to the first phase, T-allele carriers excreted comparably more sodium chloride in a gene-dose-dependent manner.
The GNB3 polymorphism and two formerly reported polymorphisms also affected volume excretion. The subjects more sodium chloride per two Arg152 alleles (P ¼ 0.05 and 0.007, Figure 2 ). The time course of the urinary sodium chloride excretion by ANP genotype suggested a continuous influence. The effects of both polymorphisms were medium: 76 and 67% of the mean standard deviation of 4.2 g d -1 . Taken together, these effects sum up to a very large effect. In its extremes, and neglecting the possibility of counterregulation, carriers of Met/Met and Ter/Ter would excrete 6.0 g less sodium chloride per day than Val/Val and Arg/Arg homozygotes. This reflects the 1.4-fold of the mean standard deviation and 30% of the mean sodium chloride excretion of 20.2 g over 1 day after loop diuretic intake. One should note, however, that these calculations are extrapolations, which are based mainly on heterozygotes.
Potassium and Calcium
The ANP polymorphism Ter152Arg and one formerly reported polymorphism commonly affected the urinary potassium excretion (grey shaded bars in Figure 5 , given effect sizes are from common ANCOVA, original data in Table 3 ). Carriers of two Arg152 alleles excreted 420 mg d -1 less potassium compared to carriers of two Ter152 alleles (P ¼ 0.023). With 57% of 737 mg d -1 standard deviation the Ter152Arg polymorphism had a medium size effect. Compared with the mean total potassium excretion, the effect was 14% of 2872 mg d -1 . The time course of the urinary potassium excretion by ANP genotype suggested a continuous influence over time. With the other ANP polymorphism, the subjects excreted 154 mg more potassium per two Met32 alleles (P40.2). Thereby, as with sodium chloride, the directions of association with the two ANP polymorphisms opposed each other.
The polymorphisms in ACE, ADD1 and GNB3 and two formerly reported polymorphisms affected the urinary calcium excretion (grey shaded bars in Figure 6 , given effect sizes are from common ANCOVA). The subjects excreted 38 mg d -1 more calcium per two ACE D-alleles (P ¼ 0.006) and 44 mg d -1 more calcium per two ADD1 Trp-alleles (P ¼ 0.023). The subjects excreted 42 mg d -1 less calcium per two GNB3 T-alleles (P ¼ 0.008). The polymorphisms' effects were, therefore, medium sized with 47, 54 and 52% of the 81 mg d -1 standard deviation. Compared with the mean urinary calcium excretion, the effect sizes of the polymorphisms were 15, 17 and 16% of 261 mg d -1 . The influence of the ACE and the ADD1 polymorphism was pronounced during the later phases from 6 h after drug intake and particularly during the 10-24 h collection period. The direction of the genotype-phenotype association of the GNB3 polymorphism slightly turned during the 24 h alike with sodium chloride.
Genetic versus pharmacokinetic impact
Three polymorphisms have formerly been reported to affect the loop diuretic response: NCC's Gly264Ala, the haplotype H2_1 in ENaC's b-subunit and Leu649Leu in ENaC's g-subunit. The statistically significant effects (grey bars in Figures 2, 5 and 6, original data in Table 3 ) were: carriers of NCC Ala264-alleles excreted more sodium chloride and more potassium. Carriers of H2_1 excreted more sodium chloride and volume, but less calcium. And carriers of the minor allele of Leu649Leu excreted less volume and less calcium. The phenotype associations were generally similar with and without inclusion of the newly investigated polymorphisms. The effect size of the significant phenotype associations was within ± 12% of the effect size estimated without inclusion of the five newly investigated polymorphisms with one exception: The effect of Leu649-Leu in ENaC's g-subunit on calcium excretion was 82 mg (Po0.001) with inclusion, instead of 56 mg (P ¼ 0.001) per two minor alleles without inclusion of the five newly investigated polymorphisms.
Together, the five newly and the three formerly investigated polymorphisms, were attributed about one-sixth of the variation in the loop diuretic drug response. Concretely, the eight polymorphisms were attributed 20, 15, 10 and 23% of the total variation in the urinary sodium chloride, volume, potassium and calcium excretion after loop diuretic drug intake, respectively (ANCOVA). The fractions of variation attributed to the polymorphisms were similar among the three-loop diuretics (Table 4) . Total variation includes inter-individual, intra-individual and residual variation. Therefore, the true impact is higher than the attributed fractions of variation.
The impact of the polymorphisms exceeded the impact of inter-individual differences in pharmacokinetics (Figure 7) . The latter cumulate in inter-individual differences in urinary drug excretion, which, in the case of loop diuretics, determines the drug concentrations at the site of action. The differences in the urinary 24-h excretion of the loop diuretics were attributed about one-tenth of the variation in the loop diuretic drug effect, namely 13, 10, 11 and 6% (ANCOVA) of the variation in the urinary excretion of sodium chloride, volume, potassium and calcium, respectively. This is less than the sixth of variation attributed to the genetic polymorphisms.
Discussion
Each of the five polymorphisms, which affect the thiazide diuretic response, has at least one medium size effect on the loop diuretic response in healthy volunteers. Together, the five newly and the three formerly investigated polymorphisms explain one-sixth of the inter-individual differences in the urinary electrolyte excretion. This is more than the tenth of variation explained by differences in the urinary excretion of the loop diuretics. One may anticipate that onesixth is a fraction which significantly impacts the therapeutic outcome in the fragile patients who take loop diuretics. 
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Two advantages of our study arose from analyzing the five polymorphisms concomitantly with the three polymorphisms, which had formerly been associated with loop diuretic effects. 1 First, we could adequately control for the known impact of these polymorphisms. Second, the common analysis allowed estimating the common genetic impact. A third advantage of our study is that the polymorphisms were investigated in parallel to a similarly designed and comparably large study on hydrochlorothiazide's diuretic effect.
The altogether eight genetic polymorphisms influence the inter-individual differences in the loop diuretic response stronger than the inter-individual differences in the urinary loop diuretic excretion do. The polymorphisms explained 20% of the variation in the sodium chloride excretion over 24 h ( Figure 7 ) and 15, 10 and 23% of the variation in the urinary volume, potassium and calcium excretion. It may be noticed that none of these eight polymorphisms affects the primary pharmacological target of the loop diuretics, the sodium-potassium-di-chloride-cotransporter 2, but rather downstream responses. As the overall variation included intra-individual and residual variation, the true genetic impact is higher than these values.
GNB3
Carriers of the T-allele of the GNB3 polymorphism excreted less sodium chloride, less volume and less calcium (Figures 2  and 6 ). The pattern implies that this G nucleotide b-subunit considerably affects the salt reabsorption in the early part of ENaC-β H2_1
ENaC-g Leu649Leu Figure 5 Impact of the polymorphisms on the urinary potassium excretion. The figure depicts how strongly the named polymorphisms affect the urinary excretion of potassium. Bars denote the mean ± s.e.m. effect per two minor alleles. Bars to the left denote lower excretion, bars to the right higher excretion. In homozygous carriers of the respective minor allele, the difference compared with homozygous carriers of the major allele, is twice the depicted size. Data are from common covariance analyses, including the eight named polymorphisms. Grey bar filling denotes Po0.05. For abbreviations of the polymorphisms see legend to Figure 2. the distal convoluted tubule. Those cells reabsorb sodium and chloride through the NCC and also account for a major part of the urinary calcium reabsorption. The circadian rhythm in the direction of association with the urinary excretion may be associated with the time course of adrenergic counterregulation to loop diuretic intake ( Figure 4 ). GNB3 mediates adrenergic signals. Adrenergic activity is high after loop diuretic intake to compensate for the loss of volume and electrolytes. Later, the adrenergic activity fades. Different levels of GNB3's signaling activity during the first hours after loop diuretic intake may cause oppositely different levels of counter-regulation. In addition, the turn in the direction of association may depend on the low adrenergic activity during night. Speculations, however, which need to be verified. Findings with hydrochlorothiazide corroborate the assumptions. After hydrochlorothiazide, the direction of GNB3's genotype-phenotype association turned during the 24-h study period, alike with the loop diuretics: T-allele carriers excreted less up to 10 h after drug intake and more, thereafter (data on file).
Given that the size of the impact of GNB3's polymorphism depends on adrenergic activity, one may anticipate a larger effect size, than that reported in this study, in patients with continuously high adrenergic activity. Adrenergic activity is continuously high in many patients taking loop diuretics for heart failure and patients with renal dysfunction.
ANP
The ANP polymorphisms had the largest effect on the urinary sodium chloride excretion. The impact was particularly large, when the two polymorphisms were considered together. However, we did not expect the minor alleles of the two investigated ANP polymorphisms to affect the urinary electrolyte excretion diametrically opposed. So far, parallel effects of the two minor alleles have been reported. Both are cardio-vascular risk alleles, affect outcome measures after chlortalidone in parallel and are associated with high potassium excretion after hydrochlorothiazide. 5, 6 The impact of the more frequent ANP polymorphism Ter152Arg (Ter, standing for termination, denotes a stop codon) was in accordance with its impact on thiazideinduced diuresis. Carriers of the Arg152-allele excreted more sodium, chloride and potassium (Figures 2 and 5 ). After hydrochlorothiazide, Arg-allele carriers also excrete more potassium; 6 and tended to excrete more sodium chloride (data on file). The impact of the other ANP polymorphism Val32Met better fits an allele exerting cardiovascular risk by high renal salt reabsorption (Figures 2 and 5 ). These results, however, seem to contradict the finding of comparably high potassium excretion in Met32-carriers after hydrochlorothiazide. 6 We may have observed the apparently contradictory findings with Val32Met by chance due to the low number of nine heterozygous and no homozygous Met32-allele carrier in this study. However, if the finding is confirmed, the two minor ANP alleles may differentially affect the multiple renal effects of the atrial natriuretic peptide. Figure 7 Genetic vs pharmacokinetic impact on the urinary sodium chloride excretion. The figure depicts the fractions (%) of the variation in the urinary sodium chloride excretion over 24 h after loop diuretic drug intake, which were attributed to the eight genetic polymorphisms and to inter-individual differences in the 24 h excretion of the loop diuretics. Fractions attributed to the single polymorphisms are shown top down in the order as in the legend to Figure 2 .
ACE I/D
Carriers of the deletion allele (D-allele) may be especially prone to osteoporosis and bone fractures, when on loop diuretic therapy. Loop diuretics promote calciuresis and potentially, thereby, osteoporosis. 13 Carriers of the deletion allele (D-allele) of the ACE I/D polymorphism excreted more calcium than carriers of the insertion allele ( Figure 6 ). Potentially, D-allele carriers may be susceptible to osteoporosis in general.
Our findings are in line with the assumption of low sodium chloride reabsorption through NCC in D-allele carriers, which we hypothesized from our findings with hydrochlorothiazide. With hydrochlorothiazide, D-allele carriers excrete less additional potassium and tended to excrete less additional sodium chloride after hydrochlorothiazide intake. 4 The D-allele is associated with more ACE in plasma and tissue. 7 As Figure 8 depicts, in the consequence of high ACE activity, the blood pressure in D-allele carriers may particularly rely on angiotensin II-mediated vasoconstriction plus aldosterone-mediated salt reabsorption through the ENaC. After loop diuretic intake, besides calcium, D-allele carriers also tended to excrete more sodium chloride and potassium (Figures 2 and 5) . When loop diuretics inhibit the sodium-potassium-di-chloridecotransporter 2, higher amounts of electrolytes pass on to the NCC. When the NCC system is weakly active, it should antagonize such an increased electrolyte load weakly and this is what we found.
ADD1
Our findings fit the findings with hydrochlorothiazide. Carriers of the Trp-allele of ADD1's Gly460Trp polymorphism excreted more calcium than carriers of the Gly-allele ( Figure  6 ). Trp-allele carriers also tended to excrete more potassium ( Figure 5) ; a tendency to excrete less sodium chloride was inconsistent among the three loop diuretics. After hydrochlorothiazide, healthy Trp-allele carriers also excreted more electrolytes, the effect of the polymorphism most pronounced with calcium. These findings fit that hydrochlorothiazide reduces the blood pressure stronger in Trp-allele carriers than in Gly-allele carriers. [8] [9] [10] The impact on blood pressure control with loop diuretics is unknown.
Conclusion
Eight genetic polymorphisms explain one-sixth of the interindividual differences in the diuretic response to loop diuretics. This is more than the tenth, which differences in loop diuretic excretion explain. Predicting one-sixth of the inter-individual differences may be clinically relevant. Human pharmacological studies, such as ours, can help to understand how predictors of the individual drug response act biochemically, physiologically and pharmacologically. One may notice that none of the formerly investigated sodium-potassium-di-chloride-cotransporter 2 polymorphisms, but rather polymorphisms of downstream regulatory proteins affected the loop diuretic response. However, the clinical relevance itself can only be determined in patients.
There is no guarantee that genetic polymorphisms, which affect the 24 h ion excretion in healthy subjects, also affect clinical measures or clinical outcome. In fragile patients with impaired counter-regulatory capacities, the impact of genetic polymorphisms may exceed that in healthy subjects; or, alternatively, the impact of genetic polymorphisms may be negligible and overridden by clinical criteria. Our results call to investigate the genetic impact on the clinical outcome of loop diuretic therapy. 
